Skip to main content
. 2021 Apr 21;19:2775–2789. doi: 10.1016/j.csbj.2021.03.033

Fig. 7.

Fig. 7

Immune microenvironment prediction and therapy prediction. (A) Single-cell sequencing showing relationship between DNMT1/EZH2 and immune cells based on HPA database; (B-C) Diagram showing the correlation between RiskScore and activated B cell infiltration/effector memory CD8 T cell infiltration / DNMT1/ EZH2 in ICGC (B) and TCGA (C) database; (D-E) Diagram showing the correlation between activated B cell infiltration/effector memory CD8 T cell infiltration and DNMT1/ EZH2 in ICGC (D) and TCGA (E) database; (F) Recurrence-free survival time after sorafenib treatment between high- and low-risk groups; (G) RiskScore and 4 hypoxia-related genes’ expression (DCN, DDIT4, NDRG1, PRKCA) between sorafenib non-response group and sorafenib response group; (H) RiskScore and 4 hypoxia-related genes’ expression (DCN, DDIT4, NDRG1, PRKCA) between TACE non-response group and TACE response group; (I) RiskScore and Four hub genes’ expression (DCN, DDIT4, NDRG1, PRKCA) between immunotherapy non-response group and immunotherapy response group; (J) Connectivity map analysis (CMap) showing potential inhibitors targeting the HCC hypoxia signatures.